Clinical Professor of Radiation and Cellular Oncology, University of Chicago
Radiation Oncology
Dr. William D. Bloomer, MD
|
|
Give Review
William Bloomer is an expert in the field of Radiation Oncology. He went to medical school at Jefferson Medical College. He received awards:"Chicago Magazine: Top Doctors", "Gold Medalist", "Fellow" and "Whos Who in Medicine and Healthcare". Dr. William D. Bloomer has written publications. He has 27 publications published with PubMed. The lastest publication is: 'Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.' William Bloomer is registered with Medicare and accepts Medicare payments.
Publications
- Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.
- Nitro(triazole/imidazole)-based amides/sulfonamides as antitubercular agents.
- Novel 3-nitro-1H-1,2,4-triazole-based compounds as potential anti-Chagasic drugs: in vivo studies.
- Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents.
- Novel 3-Nitro-1H-1,2,4-triazole-Based Amides and Sulfonamides as Potential Antitrypanosomal Agents.
- Novel 3-Nitro-1H-1,2,4-triazole-Based Aliphatic and Aromatic Amines as Anti-Chagasic Agents.
- Hypoxia-dependent retinal toxicity of NLCQ-1 (NSC 709257) in BALB/c mice. Comparison with tirapazamine.
- Investigational new drug-directed, 5-day repeat dose toxicity study of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) ad...
- Investigational new drug-directed toxicology and pharmacokinetic study of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257)...
- Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore.
- NLNQ-1, a 2-[3-(2-nitro-1-imidazolyl) propylamino]-3-chloro-1,4-naphthoquinone, as a hypoxia-selective cytotoxin and radiosensitizer.
- Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts.
- NLCQ-1 and NLCQ-2, two new agents with activity against dormant Mycobacterium tuberculosis.
- DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents.
- Novel fluorinated hypoxia-targeted compounds as Non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS).
- Novel non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS). Studies in the SCCVII/C3H murine model.
- Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.
- Mechanisms involved in the potentiation of paclitaxel or 5-fU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitro.
- NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts.
- Synthesis of a novel nitroimidazole-spermidine derivative as a tumor-targeted hypoxia-selective cytotoxin.
- Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radi...
- NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug.
- Irradiation reduces interstitial fluid transport and increases the collagen content in tumors.
- Reductive metabolism of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257).
- Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts.
- Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo: comparison with tirapazamine.
Schools
Thomas Jefferson University
University Hosps
Harvard Joint Center Rad Therapy
Doctors Specialties
- Nuclear Medicine
- Radiation Oncology
- Radiology
Accepted Insurances
Awards
- Chicago Magazine: Top Doctors
- Gold Medalist
- Fellow
- Whos Who in Medicine and Healthcare
Education
-
Brigham and Women's Hospital -
Case Western Reserve University - University Hospitals -
Jefferson Medical College
Hospital
-
NorthShore University Health System
Drug Facts
| NPI NUMBER | 1033158639 | |
| NPPES Provider LastName | BLOOMER | |
| NPPES Provider FirstName | WILLIAM | |
| NPPES Provider ZIPCode | 602011718 | |
| NPPES Provider State | IL | |
| Specialty Description | Nuclear Medicine | |
| Total Claim Count | 49.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1033158639 |
| Last Name Of The Provider | BLOOMER |
| First Name Of The Provider | WILLIAM |
| View All |
Similar Doctors
|
|
Dr. Andrew G. Brandmaier, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Gary Schreiber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carlos H. Escamilla, MD |
|
|
Dr. Arif Y. Shaikh, MD |
|
|
Dr. Rafael M. Garces, MD |
|
|
Dr. Gregory A. Gergans, MD |
|
|
Dr. Ranjeev K. Nanda, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert T. Dess, MD |
|
|
Dr. Michelle S. Gentile, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander Kemel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael A. Lacombe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael N. Rozenfeld, DO |
|
|
Dr. Rajal A. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Shahid Hameed, MB
This Doctor is OpenDoctor Recommended.
|